Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

BioNTech (Germany) | Researchclopedia

Back to institutions

BioNTech (Germany)

Mainzcompany

648

Works

375,596

Citations

305

h-index

Top Research Topics

Immunotherapy and Immune Responses SARS-CoV-2 and COVID-19 Research RNA Interference and Gene Delivery

Top Researchers

Uğur Şahin Johannes Gutenberg University Mainz

722 works69,935 citationsh-index: 103

Recent Research

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial

Byoung Chul Cho,Rama Balaraman,et al.

20260 citations

Cancer Immunotherapy and Biomarkers

CAR-T cell therapy research

Monoclonal and Polyclonal Antibodies Research

Virus-based gene therapy research

Immune Cell Function and Interaction

vaccines and immunoinformatics approaches

Animal Virus Infections Studies

COVID-19 Clinical Research Studies

SARS-CoV-2 detection and testing

Özlem Türeci Johannes Gutenberg University Mainz

419 works55,125 citationsh-index: 80

Andreas Schneeweiß Goethe University Frankfurt

1,644 works52,567 citationsh-index: 98

Falk Nimmerjahn Friedrich-Alexander-Universität Erlangen-Nürnberg

323 works26,301 citationsh-index: 75

Katalin Karikó BioNTech (Germany)

145 works25,167 citationsh-index: 55

Joseph M. Braun John Brown University

835 works24,979 citationsh-index: 80

A Comprehensive Workspace for All Clinical Trials: The Clinical Trial Information System (CTIS) in Europe – Opportunities for Medical Writers

Thomas Schindler

20260 citations

11MO First disclosure of efficacy and safety data for YL202/BNT326 (HER3 ADC) from a phase II trial in patients (pts) with non-small cell lung cancer (NSCLC)

H. Liu,Z. Huang,et al.

20260 citations

439TiP ROSETTA Lung-01: A phase III, two-stage trial of pumitamig, a PD-L1 × VEGF-A bispecific antibody, plus chemotherapy versus atezolizumab + chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer

M. Reck,Özgür ÖZYILKAN,et al.

20260 citations

147TiP BNT326-02: A phase Ib/II trial of BNT326/YL202 (HER3 ADC) with pumitamig (PD-L1 × VEGF-A bsAb) in non-small cell lung cancer (NSCLC)

A. Spira,I.V. Bulat,et al.

20260 citations

149TiP ROSETTA Lung-02: A global phase II/III, randomized, open-label trial of pumitamig, a PD-L1 × VEGF-A bispecific antibody, in combination with chemotherapy in patients (pts) with first-line non-small cell lung cancer

S. Peters,Y. Lee,et al.

20260 citations